SiteOne Therapeutics develops drugs that target sodium channels, the “wiring” in the body that transmits pain signals. Because SiteOne’s targets are located in the peripheral nervous system, they should not pose the same addiction risks as opioids, which hit receptors in the central nervous system.
Vertex Pharmaceuticals is known for its cystic fibrosis drugs, but the company aims to diversify with a pipeline that reaches more therapeutic areas. CEO Reshma Kewalramani explained Vertex’s strategy during the World Medical Innovation Forum in Boston.
The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want.
Thar produces an oral version of an existing intravenous drug used to treat the estimated 80,000 Americans diagnosed annually with complex regional pain syndrome.
To Mark Publicker, a doctor in Portland, Maine, who practices addiction medicine, it’s a clear case of discrimination. You wouldn’t deprive a diabetic of insulin. You wouldn’t stop giving hypertension drugs to a patient with high blood pressure after successful treatment. You wouldn’t hold back a statin from a patient with high cholesterol. Yet Publicker’s […]
Patient-controlled infusion pumps have been in use for 40 years, and while incremental improvements have been made, error rates remain unacceptably high -- these preventable mistakes must be avoided for future patients.
Despite the many avenues for treating pain these days, the Institute of Medicine estimates that it costs the U.S. a whopping $635 billion annually in medical charges and lost productivity. That’s the problem a young San Francisco pharmaceutical startup called Adynxx is trying to address. Existing drug treatments come with unpleasant or outright dangerous side […]
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.